TrialSignal
Clinical trial intelligence report
Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT02116634-Jul 28, 2026
NCT ID
NCT02116634
Status
WITHDRAWN
Phase
PHASE1
Sponsor
Alzahra Hospital, Iran
Executive brief
Investment-Ready Snapshot
Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients is a PHASE1 clinical asset sponsored by Alzahra Hospital, Iran in Amyotrophic Lateral Sclerosis. SEO and diligence focus: mesenchymal stem cell, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02116634
Indication
Amyotrophic Lateral Sclerosis
Modality
protein therapy
Target
mesenchymal stem cell
Intervention
mesenchymal stem cell
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.